BACKGROUND AND PURPOSE: Epidermal growth factor receptor amplification is a common molecular event in glioblastomas. The purpose of this study was to examine the potential usefulness of morphologic and diffusion MR imaging signs in the prediction of epidermal growth factor receptor gene amplification status in patients with glioblastoma. MATERIALS AND METHODS: We analyzed pretreatment MR imaging scans from 147 consecutive patients with newly diagnosed glioblastoma and correlated MR imaging features with tumor epidermal growth factor receptor amplification status. The following morphologic tumor MR imaging features were qualitatively assessed: 1) border sharpness, 2) cystic/necrotic change, 3) hemorrhage, 4) T2-isointense signal, 5) restricted water diffusion, 6) nodular enhancement, 7) subependymal enhancement, and 8) multifocal discontinuous enhancement. A total of 142 patients had DWI available for quantitative analysis. ADC maps were calculated, and the ADCmean, ADCmin, ADCmax, ADCROI, and ADCratio were measured. RESULTS: Epidermal growth factor receptor amplification was present in 60 patients (40.8%) and absent in 87 patients (59.2%). Restricted water diffusion correlated with epidermal growth factor receptor amplification (P = .04), whereas the other 7 morphologic MR imaging signs did not (P > .12). Quantitative DWI analysis found that all ADC measurements correlated with epidermal growth factor receptor amplification, with the highest correlations found with ADCROI (P = .0003) and ADCmean (P = .0007). CONCLUSIONS: Our results suggest a role for diffusion MR imaging in the determination of epidermal growth factor receptor amplification status in glioblastoma. Additional work is necessary to confirm these results and isolate new imaging biomarkers capable of noninvasively characterizing the molecular status of these tumors.
BACKGROUND AND PURPOSE:Epidermal growth factor receptor amplification is a common molecular event in glioblastomas. The purpose of this study was to examine the potential usefulness of morphologic and diffusion MR imaging signs in the prediction of epidermal growth factor receptor gene amplification status in patients with glioblastoma. MATERIALS AND METHODS: We analyzed pretreatment MR imaging scans from 147 consecutive patients with newly diagnosed glioblastoma and correlated MR imaging features with tumorepidermal growth factor receptor amplification status. The following morphologic tumor MR imaging features were qualitatively assessed: 1) border sharpness, 2) cystic/necrotic change, 3) hemorrhage, 4) T2-isointense signal, 5) restrictedwater diffusion, 6) nodular enhancement, 7) subependymal enhancement, and 8) multifocal discontinuous enhancement. A total of 142 patients had DWI available for quantitative analysis. ADC maps were calculated, and the ADCmean, ADCmin, ADCmax, ADCROI, and ADCratio were measured. RESULTS:Epidermal growth factor receptor amplification was present in 60 patients (40.8%) and absent in 87 patients (59.2%). Restrictedwater diffusion correlated with epidermal growth factor receptor amplification (P = .04), whereas the other 7 morphologic MR imaging signs did not (P > .12). Quantitative DWI analysis found that all ADC measurements correlated with epidermal growth factor receptor amplification, with the highest correlations found with ADCROI (P = .0003) and ADCmean (P = .0007). CONCLUSIONS: Our results suggest a role for diffusion MR imaging in the determination of epidermal growth factor receptor amplification status in glioblastoma. Additional work is necessary to confirm these results and isolate new imaging biomarkers capable of noninvasively characterizing the molecular status of these tumors.
Authors: Ajay Gupta; Antonio M P Omuro; Akash D Shah; Jerome J Graber; Weiji Shi; Zhigang Zhang; Robert J Young Journal: Neuroradiology Date: 2011-10-18 Impact factor: 2.804
Authors: Whitney B Pope; Hyun J Kim; Jing Huo; Jeffry Alger; Matthew S Brown; David Gjertson; Victor Sai; Jonathan R Young; Leena Tekchandani; Timothy Cloughesy; Paul S Mischel; Albert Lai; Phioanh Nghiemphu; Syed Rahmanuddin; Jonathan Goldin Journal: Radiology Date: 2009-07 Impact factor: 11.105
Authors: Ramon F Barajas; Joanna J Phillips; Rupa Parvataneni; Annette Molinaro; Emma Essock-Burns; Gabriela Bourne; Andrew T Parsa; Manish K Aghi; Michael W McDermott; Mitchel S Berger; Soonmee Cha; Susan M Chang; Sarah J Nelson Journal: Neuro Oncol Date: 2012-06-18 Impact factor: 12.300
Authors: Maximilian Diehn; Christine Nardini; David S Wang; Susan McGovern; Mahesh Jayaraman; Yu Liang; Kenneth Aldape; Soonmee Cha; Michael D Kuo Journal: Proc Natl Acad Sci U S A Date: 2008-03-24 Impact factor: 11.205
Authors: Daniel A Hamstra; Craig J Galbán; Charles R Meyer; Timothy D Johnson; Pia C Sundgren; Christina Tsien; Theodore S Lawrence; Larry Junck; David J Ross; Alnawaz Rehemtulla; Brian D Ross; Thomas L Chenevert Journal: J Clin Oncol Date: 2008-06-09 Impact factor: 44.544
Authors: Anita Lal; Chad A Glazer; Holly M Martinson; Henry S Friedman; Gary E Archer; John H Sampson; Gregory J Riggins Journal: Cancer Res Date: 2002-06-15 Impact factor: 12.701
Authors: Jayashree Kalpathy-Cramer; Elizabeth R Gerstner; Kyrre E Emblem; Ovidiu Andronesi; Bruce Rosen Journal: Cancer Res Date: 2014-09-01 Impact factor: 12.701
Authors: A Gupta; R J Young; A D Shah; A D Schweitzer; J J Graber; W Shi; Z Zhang; J Huse; A M P Omuro Journal: Clin Neuroradiol Date: 2014-01-29 Impact factor: 3.649
Authors: Dieter Henrik Heiland; Carl Philipp Simon-Gabriel; Theo Demerath; Gerrit Haaker; Dietmar Pfeifer; Elias Kellner; Valerij G Kiselev; Ori Staszewski; Horst Urbach; Astrid Weyerbrock; Irina Mader Journal: Sci Rep Date: 2017-03-07 Impact factor: 4.379